Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-04-16 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度履职情况报告" (2024 Annual Performance Report) of the Board Audit Committee of Chengdu Oukang Pharmaceutical Co., Ltd. It details the audit committee's activities, meetings, supervision of external auditors, internal audit guidance, and overall evaluation for the year 2024. The content focuses on the audit committee's duties and oversight rather than presenting full financial statements or a comprehensive annual report. The document length is 2352 characters, which is relatively short and more of a committee report rather than a full audit report or annual report. It is not a certification or a brief announcement but a detailed report on the audit committee's work. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports on audit activities, excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2024
2025-04-16 Chinese
2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024年度内部控制自我评价报告' which translates to '2024 Annual Internal Control Self-Evaluation Report'. It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2024. The content includes descriptions of internal control environment, control measures, evaluation standards, and conclusions about the effectiveness of internal controls, both financial and non-financial. It is not an announcement of a report publication but the report itself, containing substantive evaluation and analysis. The document is not a full annual report (10-K), but a specialized internal control evaluation report, which fits the category of Audit Report / Information (AR) as it relates to internal control evaluation and audit-related information. The document length (7768 characters) supports it being a full report rather than a brief announcement. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-16 Chinese
第四届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chengdu Oukang Pharmaceutical Co., Ltd. regarding the approval of various proposals including the 2024 Annual Report, financial statements, budget, dividend distribution plan, remuneration, leasing, financing, internal control report, and special audit reports. It references the 2024 Annual Report and other reports that have been disclosed separately on the Beijing Stock Exchange information platform. The document itself does not contain the full annual report or detailed financial statements but rather the resolutions approving these reports and proposals, which will be submitted to the shareholders' meeting for further approval. The document length is about 5,444 characters, and it mainly serves as an official announcement of meeting resolutions rather than the full report. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of meeting resolutions and approvals related to the annual report and other matters, not the annual report itself.
2025-04-16 Chinese
申万宏源证券承销保荐有限责任公司关于成都欧康医药股份有限公司2024年度募集资金存放与使用情况的专项核查报告
Regulatory Filings
2025-04-16 Chinese
关于2025年度公司及子公司向银行申请综合授信额暨关联担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Chengdu Oukang Pharmaceutical Co., Ltd. regarding the application for a comprehensive credit line and related guarantees from banks for the year 2025. It details the credit amount, types of credit facilities, collateral, and the approval process by the board and supervisory committee. There are no financial statements or detailed financial performance data included. The document is a financing update about the company's capital structure and credit facilities. It is not an annual or interim report, nor an earnings release or audit report. The content fits the category of Capital/Financing Update (CAP). The document length is 1734 characters, which is consistent with an announcement rather than a full report.
2025-04-16 Chinese
关于成都欧康医药股份有限公司非经营性资金占用及其他关联资金往来情况专项审核说明
Regulatory Filings
2025-04-16 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.